Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CCR9 encodes a beta chemokine receptor, which is predicted to be a seven transmembrane protein similar to G protein-coupled receptors. Additionally we are shipping Chemokine (C-C Motif) Receptor 9 Proteins (4) and Chemokine (C-C Motif) Receptor 9 Kits (1) and many more products for this protein.
Showing 10 out of 190 products:
Human Polyclonal CCR9 Primary Antibody for WB - ABIN657775
Han, Lan, Park, Lee, Park, Ahn, Shin, Kang, Koo, Seo, Choi, Ahn, Chanock, Kim, Rothman, Kang: Polymorphisms in innate immunity genes and risk of childhood leukemia. in Human immunology 2010
Show all 4 references for ABIN657775
Mouse (Murine) Monoclonal CCR9 Primary Antibody for FACS - ABIN2663131
Wurbel, Malissen, Campbell: Complex regulation of CCR9 at multiple discrete stages of T cell development. in European journal of immunology 2006
Show all 3 references for ABIN2663131
Human Polyclonal CCR9 Primary Antibody for FACS, IHC (p) - ABIN152131
Zaballos, Gutiérrez, Varona, Ardavín, Márquez: Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. in Journal of immunology (Baltimore, Md. : 1950) 1999
Mouse (Murine) CCR9 Primary Antibody for ICC, IHC (fro) - ABIN1042586
Pabst, Ohl, Wendland, Wurbel, Kremmer, Malissen, Förster: Chemokine receptor CCR9 contributes to the localization of plasma cells to the small intestine. in The Journal of experimental medicine 2004
CCR9 and Integrin-beta7 expression has a differential effect on graft fate during acute graft-versus-host disease (GVHD) of the liver depending on the GVHD target tissue.
data indicate that in addition to acting as a gut (show GUSB Antibodies)-homing molecule, CCR9 signaling shapes immune responses by inhibiting Treg cell development
Data suggest that blocking CC chemokine receptor (show CCR1 Antibodies) 9 (CCR9) may represent a novel safe therapy for rheumatoid arthritis (RA).
activation of Notch1 (show NOTCH1 Antibodies) has a dominant-negative effect on Ccr9 transcription and that Notch1 (show NOTCH1 Antibodies) and E proteins control the dynamic expression of Ccr9 during T cell development.
ACKR2 can regulate fetal (show CCL1 Antibodies) growth, placental structure, and neonatal mortality in mice.
Further examination revealed that proximity of pro-lymphangiogenic macrophages to developing lymphatic vessel surfaces is increased in ACKR2-deficient mice and reduced in CCR2-deficient mice.
some cells, including plasmacytoid dendritic cells, can express both CCR2 (show CCR2 Antibodies) and ACKR2; that Ly6C(high) monocytes have particularly strong CCL2 (show CCL2 Antibodies)-scavenging potential in vitro and in vivo; and that CCR2 (show CCR2 Antibodies) is a much more effective CCL2 (show CCL2 Antibodies) scavenger than ACKR2.
CCR9/CCL25 (show CCL25 Antibodies) is involved in acute skin transplantation rejection and anti-CCL25 (show CCL25 Antibodies) strategies might be useful in preventing acute rejection.
Accumulated CD11b (show ITGAM Antibodies)(+) macrophages are critical for activating hepatic stellate cells through the CCR9/CCL25 (show CCL25 Antibodies) axis and therefore promote liver fibrosis.
CCR9-expressed plasmacytoid dendritic cells are possibly small intestine regulatory, antigen-presenting cells that suppress intestinal inflammation.
Studies indicate important roles played by chemokine ligand 25 (CCL25 (show CCL25 Antibodies))/chemokine receptor (show CCR1 Antibodies) 9 (CCR9) in tumorigenesis, tumor chemoresistance and metastasis.
CCR9 mRNA and protein levels were significantly increased in the nasopharyngeal carcinoma group compared with the control group.
CCR9-CCL25 (show CCL25 Antibodies) interaction promoted proliferation and suppressed apoptosis of non-small cell lung cancer cells by activating the PI3K (show PIK3CA Antibodies)/Akt (show AKT1 Antibodies) pathway.
CCR9 could be beneficial in predicting lymph node metastasis, and it might act as a novel prognostic biomarker for lung adenocarcinoma.
We also show that primary tumors can be modeled in immunocompetent mice by microinjecting CCR9-expressing cancer cell lines into early-stage mouse blastocysts, which induces central immune tolerance
High CCR9 expression is associated with the pathogenesis of ulcerative colitis.
Expression of CCR9 and CCL25 (show CCL25 Antibodies), the only natural ligand of CCR9, was significantly higher (p<0.0001) in NSCLC tissues and serum respectively, compared to their respective controls.
ACKR2 mediates chemokine (show CCL1 Antibodies) scavenging by primary human trophoblasts.
The protein encoded by this gene is a member of the beta chemokine receptor family. It is predicted to be a seven transmembrane protein similar to G protein-coupled receptors. Chemokines and their receptors are key regulators of the thymocytes migration and maturation in normal and inflammation conditions. The specific ligand of this receptor is CCL25. It has been found that this gene is differentially expressed by T lymphocytes of small intestine and colon, suggested a role in the thymocytes recruitment and development that may permit functional specialization of immune responses in different segment of the gastrointestinal tract. This gene is mapped to the chemokine receptor gene cluster region. Two alternatively spliced transcript variants have been described. Multiple transcript variants encoding different isoforms have been found for this gene.
C-C chemokine receptor D6
, D6 beta-chemokine receptor
, chemokine binding protein 2
, chemokine-binding protein 2
, chemokine-binding protein D6
, CC-chemokine-binding receptor JAB61
, chemokine (C-C motif) receptor 9
, chemokine (C-C) receptor 9
, chemokine receptor CCR-10
, chemokine receptor CCR-9
, chemokine receptor D6
, C-C chemokine receptor type 9
, G protein-coupled receptor 28
, C-C CKR-9
, chemokine C-C receptor 10
, chemokine C-C motif receptor 9